• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • SPG302
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
  • Events/Programs
    • Calendar of Events/Programs
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

SEED Grant Program

The SEED Grant Program: Supporting Excellence, Equity, and Discovery for ALS/MND

ALS/MND affects people in every part of the world. Yet many regions remain significantly under-represented in ALS/MND research — not because the need is less, but because the foundational infrastructure for research participation is still developing.

The SEED (Supporting Excellence, Equity, and Discovery for ALS/MND) Grant Program was created to help change that.

About SEED

SEED provides early-stage funding to support efforts that strengthen ALS/MND research infrastructure and readiness in low-income, lower-middle-income, and upper-middle-income countries, based on World Bank country income classifications. The program is made possible through founding support from FightMND and ALS Canada, with growing support from across the global ALS/MND community.

Eligible projects focus on practical steps that create, connect, or strengthen the people, systems, partnerships, data pathways, and infrastructure needed for ALS/MND research. These efforts may help local or regional teams prepare for work in one or more areas, including ALS/MND registries, biobanking preparation, data collection pathways, genetic and epidemiological studies, clinical trial readiness, or locally relevant pilot work.

The goal is to support local leaders, institutions, and networks as they build the foundations needed for future ALS/MND research, collaboration, and larger-scale funding.

Who Can Apply

SEED is open to:

  • Researchers
  • Clinicians
  • Academic institutions
  • Hospitals and clinics
  • Research networks
  • Multi-site collaborations
  • Regional partnerships

Applications may be submitted by individual organizations or collaborative groups.

Collaborations with high-income countries are welcome when they strengthen research readiness, leadership, ownership, and benefit within an eligible country.

How to Apply

Applications open June 21, 2026, and close September 1, 2026. Applications must be submitted through the SEED Application Portal, which will be open on June 21.

Recipients will be announced at the Alliance Meeting on December 5-6, 2026 in Amsterdam, Netherlands. 

Funding Available

Applicants may request up to US$50,000. The total number of awards will depend on available funding and the size of the selected proposals.

The maximum award amount is inclusive of all costs, including direct costs, indirect costs, institutional overheads, and any applicable taxes or fees. Indirect costs, including institutional overheads, may not exceed 5% of the total budget requested.

Applicants do not need to request the maximum amount. Smaller, focused proposals may be appropriate if the project has a clear purpose, a realistic plan, and a measurable outcome.

Questions

When the application portal opens on June 21, you will find more information, such as Frequently Asked Questions and templates. Please review this information before reaching out. 

For questions about eligibility, project fit, application requirements, or budget preparation, contact seed@als-mnd.org.

Primary Sidebar

  • Ali Var, Turkey

    Ali Var, Turkey

  • Zabun Nassar, MND Association, Diagnosed 2016, England

    Zabun Nassar, MND Association, Diagnosed 2016, England

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

    Anthony (Tony) Lynch, MND New South Wales, Diagnosed 2016, Australia

  • Kirsten Harley,  Diagnosed 2013,  Australia

    Kirsten Harley, Diagnosed 2013, Australia

  • Claudia Gotti, Brazil

    Claudia Gotti, Brazil

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

    Hans Dieter Olszewski, Diagnosed 2010 , DGM, Germany

  • Shay Rishoni

    Shay Rishoni

  • Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

    Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

  • Chih Ching Darren Wong, MND Malaysia

    Chih Ching Darren Wong, MND Malaysia

  • Norm MacIsaac,  ALS Society of Canada,  ALS Society of Quebec,  Diagnosed 2014

    Norm MacIsaac, ALS Society of Canada, ALS Society of Quebec, Diagnosed 2014

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Maurice LeClerc, ALS Canada

    Maurice LeClerc, ALS Canada

  • Jan Zuring, Diagnosed 2010 , The Netherlands

    Jan Zuring, Diagnosed 2010 , The Netherlands

  • Daniel Hare

    Daniel Hare

  • Lombana, Spain

    Lombana, Spain

  • Ali Var, Turkey

    Ali Var, Turkey

  • Monica Soriano, Diagnosed 2011 ,  Asociación ELA , Argentina

    Monica Soriano, Diagnosed 2011 , Asociación ELA , Argentina

  • Phil Rossall, MND-Association, UK

    Phil Rossall, MND-Association, UK

  • Glen Elison,  ALS Hope Foundation,  Diagnosed 2019,  USA

    Glen Elison, ALS Hope Foundation, Diagnosed 2019, USA

  • Chen Chun-Chin

    Chen Chun-Chin

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Maurice Leclerc, Canada

    Maurice Leclerc, Canada

  • Denis Blais, Diagnosed 2015 , ALS Canada

    Denis Blais, Diagnosed 2015 , ALS Canada

  • Peng Yi-Wen

    Peng Yi-Wen

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

    Jose Rivero Muñoz, Diagnosed 2015, FYADENMAC, Mexico

  • Leon Ryba, Asociación ELA Argentina

    Leon Ryba, Asociación ELA Argentina

  • Andrea Zicchieri, Associazione conSLAncio Onlus, Italy

    Andrea Zicchieri, Associazione conSLAncio Onlus, Italy
    AndreaZicchieri_conSLAncioItaly

  • Ada Garrido Benavidez, Diagnosed 2016,  FYADENMAC, Mexico

    Ada Garrido Benavidez, Diagnosed 2016, FYADENMAC, Mexico

  • Tison, USA

    Tison, USA

  • Mauril Belanger

    Mauril Belanger

  • Susan Keldani, Les Turner ALS Foundation, USA

    Susan Keldani, Les Turner ALS Foundation, USA

  • Christian Bär, Germany

    Christian Bär, Germany

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

  • Aida Trzmiel de Guterman, Asociacion ELA Argentina, Diagnosed 2007, Argentina

    Aida Trzmiel de Guterman, Asociacion ELA Argentina, Diagnosed 2007, Argentina

  • Natalya Rybakova, Russian Charity ALS Foundation

    Natalya Rybakova, Russian Charity ALS Foundation

  • Alberto Baez Murillo, Colombia

    Alberto Baez Murillo, Colombia

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Imelda Arenas, ACELA, Colombia

    Imelda Arenas, ACELA, Colombia

  • Tammy Moore and Eddy Lefrancois

    Tammy Moore and Eddy Lefrancois

  • Ian Gale, MND Australia

    Ian Gale, MND Australia

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • 393647_2252248542053_984912751_n

    393647_2252248542053_984912751_n

  • John and Loretta Russo, USA

    John and Loretta Russo, USA
    final3878

  • Liam Dwyer, England

    Liam Dwyer, England

  • Greg Heydet, ALS Hope Foundation, USA

    Greg Heydet, ALS Hope Foundation, USA

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

  • David Watson,  MND Scotland,  Diagnosed 2018

    David Watson, MND Scotland, Diagnosed 2018

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login